- Home
- MSW vs CDTX Comparison
MSW vs CDTX Comparison
Compare MSW & CDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MSW
- CDTX
- Stock Information
- Founded
- MSW 2012
- CDTX 2012
- Country
- MSW Hong Kong
- CDTX United States
- Employees
- MSW N/A
- CDTX N/A
- Industry
- MSW
- CDTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MSW
- CDTX Health Care
- Exchange
- MSW NYSE
- CDTX Nasdaq
- Market Cap
- MSW 62.8M
- CDTX 980.1M
- IPO Year
- MSW 2024
- CDTX 2015
- Fundamental
- Price
- MSW $4.66
- CDTX $48.89
- Analyst Decision
- MSW
- CDTX Strong Buy
- Analyst Count
- MSW 0
- CDTX 11
- Target Price
- MSW N/A
- CDTX $52.11
- AVG Volume (30 Days)
- MSW 93.5K
- CDTX 1.4M
- Earning Date
- MSW 08-25-2025
- CDTX 08-12-2025
- Dividend Yield
- MSW N/A
- CDTX N/A
- EPS Growth
- MSW 18.78
- CDTX N/A
- EPS
- MSW 0.20
- CDTX N/A
- Revenue
- MSW $31,769,612.00
- CDTX $302,000.00
- Revenue This Year
- MSW N/A
- CDTX N/A
- Revenue Next Year
- MSW N/A
- CDTX N/A
- P/E Ratio
- MSW $22.79
- CDTX N/A
- Revenue Growth
- MSW 30.91
- CDTX N/A
- 52 Week Low
- MSW $2.12
- CDTX $10.14
- 52 Week High
- MSW $10.58
- CDTX $56.83
- Technical
- Relative Strength Index (RSI)
- MSW N/A
- CDTX 73.52
- Support Level
- MSW N/A
- CDTX $45.59
- Resistance Level
- MSW N/A
- CDTX $52.33
- Average True Range (ATR)
- MSW 0.00
- CDTX 5.13
- MACD
- MSW 0.00
- CDTX 0.22
- Stochastic Oscillator
- MSW 0.00
- CDTX 61.27
About MSW MING SHING GROUP HOLDINGS LIMITED
Ming Shing Group Holdings Ltd is a holding company, which is primarily operated through its indirectly wholly-owned Hong Kong Operating Subsidiaries, MS (HK) Engineering Limited and MS Engineering Co., Limited. It is engaged in wet trades works, such as plastering works, tile laying works, brick laying works, floor screeding works and marble works. the company is mainly engaged in private-sector projects in Hong Kong. Its private sector projects mainly involve private residential developments and commercial developments. The project owners of its private sector projects are generally property developers, and its customers are generally main contractors and wet trades work subcontractors engaged under such projects.
About CDTX Cidara Therapeutics Inc.
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.